Steroid hormone receptors in breast cancer management

Estrogen and progesterone receptors (ER and PR) have now been studied in clinical breast cancer for more than 20 years. Positive receptor status correlates with favorable prognostic features including a lower rate of cell proliferation and histologic evidence of tumor differentiation. During the first several years after diagnosis, patients with ER-positive tumors tend to have a lower recurrence rate; however, this is balanced by a higher recurrence rate in subsequent years so that the overall prognostic significance of receptor status is modest. ER and PR have their greatest utility in predicting response to hormonal therapy, both in the adjuvant setting and for advanced disease. When the assay is done properly and cut-offs for ER-negativity and positivity are defined by clinical studies of patients treated with endocrine therapy, receptor status is very helpful in identifying groups of patients who are very unlikely to benefit from hormonal therapy. Tumors that express both ER and PR have the greatest benefit from hormonal therapy, but those containing only ER or only PR still have significant responses.Two types of estrogen receptors, ERα and ERβ, have now been identified. Although there is considerable homology between these receptor forms, they appear to have important structural and functional differences that may be important for tissue and promoter- specific regulation of gene expression. These receptor forms, as well as ER variants and mutants, may also contribute to hormonal sensitivity and resistance. PR also exists in two forms, PRA and PRB. PRA appears to have repressor functions on both PRB and ERα, and the ratio of PRA to PRB in clinical breast tumors needs to be studied for its possible clinical relevance. Expression of receptor- interacting proteins can also modulate ER transcriptional activity, and these too need additional study to determine if they are markers of hormonal sensitivity or resistance. In summary, ER and PR status are important biomarkers that help physicians individualize therapy.

[1]  G. Greene,et al.  Immunochemical studies of estrogen receptors. , 1984, Journal of steroid biochemistry.

[2]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[3]  H. Dotzlaq Expression of Estrogen Receptor- in Human Breast Tumors , 1997 .

[4]  W. McGuire,et al.  Predicting response to endocrine therapy in human breast cancer: a hypothesis. , 1975, Science.

[5]  Å. Borg,et al.  An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. , 1993, Cancer research.

[6]  W. McGuire Estrogen receptors in human breast cancer. , 1973, The Journal of clinical investigation.

[7]  N. Gibbon CURE OF EARLY SYPHILIS. , 1963, Lancet.

[8]  W. McGuire,et al.  Multiple estrogen receptor assays in human breast cancer. , 1983, Cancer research.

[9]  R. Simon,et al.  Association between steroid hormone receptor status and disease-free interval in breast cancer. , 1979, Cancer treatment reports.

[10]  Helmut Dotzlaw,et al.  Expression of estrogen receptor-beta in human breast tumors. , 1997, The Journal of clinical endocrinology and metabolism.

[11]  W. McGuire,et al.  Estrogen receptor status as a prognostic indicator for stage I breast cancer patients , 2005, Breast Cancer Research and Treatment.

[12]  R. Schmutzler,et al.  An estrogen receptor genetic polymorphism and a history of spontaneous abortion — Correlation in women with estrogen receptor positive breast cancer but not in women with estrogen receptor negative breast cancer or in women without cancer , 2004, Breast Cancer Research and Treatment.

[13]  D. McDonnell,et al.  The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells , 1994, Molecular and cellular biology.

[14]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Walt,et al.  The surgical implications of estrophile protein estimations in carcinoma of the breast. , 1976, Surgery.

[16]  W. McGuire,et al.  Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. , 1992, Cancer research.

[17]  R. Blamey,et al.  Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. , 1978, British Journal of Cancer.

[18]  M. Lippman,et al.  Quantitative estrogen receptor analyses: The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease‐free interval , 1980, Cancer.

[19]  R. Simon,et al.  The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. , 1978, The New England journal of medicine.

[20]  S. Cowley,et al.  Estrogen Receptors α and β Form Heterodimers on DNA* , 1997, The Journal of Biological Chemistry.

[21]  K. Horwitz,et al.  The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. , 1997, Molecular endocrinology.

[22]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[23]  K. Grandien,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .

[24]  Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. , 1993 .

[25]  G. Greene,et al.  Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells , 1984, Nature.

[26]  C. Osborne,et al.  HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Blamey,et al.  Steroid receptors in early breast cancer: value in prognosis. , 1981, Journal of steroid biochemistry.

[28]  D. McDonnell,et al.  RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. , 1994, The Journal of biological chemistry.

[29]  R. Hähnel,et al.  Prognostic value of estrogen receptors in primary breast cancer , 1979, Cancer.

[30]  N. Copeland,et al.  Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. , 1997, Molecular endocrinology.

[31]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.

[32]  D. Allred,et al.  Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. , 1990, Archives of surgery.

[33]  G. T. Budd,et al.  Estrogen receptor mutations in tamoxifen-resistant breast cancer. , 1994, Cancer research.

[34]  H. Gronemeyer,et al.  Transcription activation by estrogen and progesterone receptors. , 1991, Annual review of genetics.

[35]  E. Jensen,et al.  Mechanism of action of the female sex hormones. , 1972, Annual review of biochemistry.

[36]  W. McGuire,et al.  Hormone receptors in primary and advanced breast cancer. , 1980, Clinics in endocrinology and metabolism.

[37]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[38]  K Griffiths,et al.  RELATIONSHIP OF ŒSTROGEN-RECEPTOR STATUS TO SURVIVAL IN BREAST CANCER , 1979, The Lancet.

[39]  K. Horwitz,et al.  Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. , 1993, Molecular endocrinology.

[40]  E. J. Gregory,et al.  Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. , 1977, Cancer research.

[41]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[42]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[43]  C. Redmond,et al.  Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[45]  W. McGuire,et al.  Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  S. Aamdal,et al.  Estrogen receptors and long‐term prognosis in breast cancer , 1984, Cancer.

[47]  P. Webb,et al.  Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. , 1995, Molecular endocrinology.

[48]  C. Vogel Adjuvant systemic therapy of primary breast cancer , 1988 .

[49]  R. Millis Correlation of hormone receptors with pathological features in human breast cancer , 1980, Cancer.

[50]  K. Horwitz,et al.  Nuclear receptor coactivators and corepressors. , 1996, Molecular endocrinology.

[51]  B. Katzenellenbogen,et al.  The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. , 1995, Molecular endocrinology.

[52]  R. Blamey,et al.  QUANTITATIVE OESTRADIOL RECEPTOR VALUES IN PRIMARY BREAST CANCER AND RESPONSE OF METASTASES TO ENDOCRINE THERAPY , 1981, The Lancet.

[53]  D. Chalbos,et al.  Differential effect of forms A and B of human progesterone receptor on estradiol-dependent transcription. , 1994, The Journal of biological chemistry.

[54]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[55]  S. Schreiber,et al.  Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase , 1997, Cell.

[56]  C. Glass,et al.  Nuclear receptor coactivators. , 1997, Current opinion in cell biology.

[57]  K. Mccarty,et al.  Elastosis in human breast cancer. Correlation with sex steroid receptors and comparison with clinical outcome. , 1984, Archives of pathology & laboratory medicine.

[58]  S. Fuqua,et al.  A role for estrogen-receptor variants in endocrine resistance , 1995 .

[59]  Predicting response to endocrine therapy in human breast cancer: a hypothesis. , 1976, Science.

[60]  J. Gorski,et al.  Hormone receptors: studies on the interaction of estrogen with the uterus. , 1968, Recent progress in hormone research.

[61]  H. Westerberg,et al.  Estrogen receptor level and other factors in early recurrence of breast cancer , 1980, International journal of cancer.

[62]  E. J. Gregory,et al.  Correlation of primary breast cancer histopathology and estrogen receptor content , 1981, Breast Cancer Research and Treatment.

[63]  W. McGuire,et al.  Multiple progesterone receptor assays in human breast cancer. , 1984, Cancer research.

[64]  S. Hilsenbeck,et al.  The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth , 2004, Cancer Chemotherapy and Pharmacology.

[65]  D. Kiang,et al.  Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. , 1978, The New England journal of medicine.

[66]  Teri Oldaker,et al.  DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients , 1993, Breast Cancer Research and Treatment.

[67]  H. Rockette,et al.  Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer , 1980, Cancer.

[68]  W. McGuire,et al.  Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Hui Li,et al.  Characterization of receptor interaction and transcriptional repression by the corepressor SMRT. , 1997, Molecular endocrinology.

[70]  J. Meyer,et al.  Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication , 1977, Cancer.

[71]  R. Paridaens,et al.  Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer , 1980, Cancer.

[72]  C. D. HAAGENSEN,et al.  Diseases of the Breast , 1972 .